In this episode of “Moving Medicine Forward,” host Jeremy Strand sits down with Brian Lawrence, Chief Financial Officer at CTI, to explore how strategic financial planning is critical to advancing clinical trials, particularly in rare disease research. Brian shares insights on balancing profitability with purpose in one of the world’s most highly regulated industries, reflecting on early career decisions, global expansion, trial funding challenges, and the growing influence of AI in finance.
00:36
Brian shares how early interests in math and accounting, along with a few great mentors, led him into finance and the clinical research space.
02:17
Why Brian opted for a smaller accounting firm over a Big Four company and how that decision shaped his career.
03:16
How his love for process improvement and early experiences with digital transformation prepared him for the dynamic contract research organization (CRO) environment.
04:03
Brian discusses CTI’s evolution: growing four times in size, expanding globally, and staying true to its rare disease focus.
05:00
The challenge of maintaining profitability while upholding the highest standards in research and compliance.
06:00
Brian explains the hidden costs of operating globally, including banking, compliance, and cybersecurity.
07:10
Why financial planning is critical in biotech, where projects can be halted suddenly due to safety or funding concerns.
09:00
How investment trends and economic shifts post-COVID have tightened budgets and forced CROs and sponsors to adapt.
10:00
Brian breaks down the financial implications of trial diversity, especially in rare diseases with complex study designs.
11:12
The role of AI and digital tools in modern CRO operations, and why CTI is taking a deliberate approach to adoption.
13:00
Brian sees technology as a way to eliminate low-value tasks and empower finance teams to focus on strategic insights.
14:00
Through initiatives like CTI Cares and “Mission Moments,” Brian explains how CTI connects internal teams to the bigger picture of patient impact.